The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Clinical outcome of concomitant chemoradiotherapy followed by adjuvant temozolomide (TMZ) therapy for high-grade gliomas (HGG) in Colombia (RedLANO registry).
L. D. Ortiz
No relevant relationships to disclose
A. F. Cardona
No relevant relationships to disclose
C. E. Fadul
No relevant relationships to disclose
A. Londono
No relevant relationships to disclose
H. A. Becerra
No relevant relationships to disclose
E. Jimenez-Hakim
No relevant relationships to disclose
C. J. Yepes
No relevant relationships to disclose
H. Carranza
No relevant relationships to disclose
R. E. Bruges Maya
No relevant relationships to disclose
C. J. Castro
No relevant relationships to disclose
C. A. Vargas
No relevant relationships to disclose